UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 7.167

Sortiert nach

Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated Meta-Analysis

JACC. Cardiovascular interventions, 2016-11, Vol.9 (22), p.2267-2276

2016

Volltextzugriff (PDF)

Sex differences in time trends in acute coronary syndrome management and in 12-month lethality: Data from the French MONICA registries

International journal of cardiology, 2022-08, Vol.361, p.103-108

2022

Volltextzugriff (PDF)

Management of Acute Coronary Syndromes

1. Aufl., 2009

Volltextzugriff (PDF)

Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing: Impact of Prasugrel and High-Dose Clopidogrel

Journal of the American College of Cardiology, 2014-03, Vol.63 (11), p.1061-1070

2014

Volltextzugriff (PDF)

Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention

JACC. Cardiovascular interventions, 2023-04, Vol.16 (7), p.829-843

2023

Volltextzugriff (PDF)

Contemporary Management of Stable Coronary Artery Disease　― Implications of the ISCHEMIA Trial

Circulation Journal, 2021/10/25, Vol.85(11), pp.1919-1927

2021

Volltextzugriff (PDF)

Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design

BMC cardiovascular disorders, 2024-01, Vol.24 (1), p.62-62, Article 62

2024

Volltextzugriff (PDF)

Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy

JACC. Cardiovascular interventions, 2010-08, Vol.3 (8), p.806-811

2010

Volltextzugriff (PDF)

The Effects of the COVID-19 Pandemic on the Clinical Practices of Cardiologists

Current problems in cardiology, 2024-01, Vol.49 (1), p.102092-102092, Article 102092

Gitmez, Mesut

2024

Volltextzugriff (PDF)

Management of acute coronary syndrome : ESC guidelines 2023

Herz, 2024-02, Vol.49 (1), p.5-14

2024

Volltextzugriff (PDF)

Impact of Society Guidelines on Trends in Use of Newer P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Journal of the American Heart Association, 2024-05, Vol.13 (9), p.e034414

2024

Volltextzugriff (PDF)

Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours

Archives of cardiovascular diseases, 2024-05, Vol.117 (5), p.351-357

2024

Volltextzugriff (PDF)

Efficacy and Safety of Ticagrelor versus Clopidogrel with Different Dosage in High-risk Patients with Acute Coronary Syndrome

International journal of cardiology, 2017-02, Vol.228, p.275-279

2017

Volltextzugriff (PDF)

Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes

JACC. Cardiovascular interventions, 2022-05, Vol.15 (9), p.999-1000

2022

Volltextzugriff (PDF)

Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes

JACC. Cardiovascular interventions, 2022-05, Vol.15 (9), p.999-999

2022

Volltextzugriff (PDF)

Evaluation of pharmacist-led transition of care program in patients with acute coronary syndrome

Journal of the American Pharmacists Association, 2024-05, Vol.64 (3), p.102023-102023, Article 102023

2024

Volltextzugriff (PDF)

Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016-12, Vol.12 (11), p.e1404

2016

Volltextzugriff (PDF)

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Journal of the American College of Cardiology, 2014-12, Vol.64 (24), p.e139-e228

2014

Volltextzugriff (PDF)

Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry

BMC cardiovascular disorders, 2023-01, Vol.23 (1), p.6-6, Article 6

2023

Volltextzugriff (PDF)

Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention

Cardiovascular revascularization medicine, 2023-03, Vol.48, p.7-14

2023

Volltextzugriff (PDF)

Timing, Selection, Modulation, and Duration of P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI

JACC. Cardiovascular interventions, 2023-01, Vol.16 (1), p.1

2023

Volltextzugriff (PDF)

Assessment of cardiac parameters after the administration of nicorandil before primary percutaneous coronary intervention

Journal of the Pakistan Medical Association, 2024-05, Vol.74 (5), p.917-921

2024

Volltextzugriff (PDF)

Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When

JACC. Cardiovascular interventions, 2020-08, Vol.13 (16), p.1847-1864

2020

Volltextzugriff (PDF)

P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes

Expert review of cardiovascular therapy, 2019-10, Vol.17 (10), p.717-727

2019

Volltextzugriff (PDF)

1 – 25 von 7.167

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

ThemaHeart Attacks

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.194)
Mit Volltextzugriff
(5.472)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(6.194)
Science & Technology
(5.201)
Life Sciences & Biomedicine
(5.082)
Male
(3.212)
Cardiovascular System & Cardiology
(3.145)
Female
(3.073)
Cardiac & Cardiovascular Systems
(2.947)
Middle Aged
(2.575)
Aged
(2.422)
Acute Coronary Syndrome
(2.350)
Acute Coronary Syndrome - Therapy
(2.222)
Treatment Outcome
(1.907)
Acute Coronary Syndromes
(1.815)
Acute Coronary Syndrome - Drug Therapy
(1.769)
Risk Factors
(1.400)
Acute Coronary Syndrome - Diagnosis
(1.089)
Platelet Aggregation Inhibitors - Therapeutic Use
(1.043)
Percutaneous Coronary Intervention
(1.002)
Cardiovascular
(867)
Time Factors
(857)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated Meta-Analysis

2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy

Sex differences in time trends in acute coronary syndrome management and in 12-month lethality: Data from the French MONICA registries

Management of Acute Coronary Syndromes

Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing: Impact of Prasugrel and High-Dose Clopidogrel

Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention

Contemporary Management of Stable Coronary Artery Disease　― Implications of the ISCHEMIA Trial

Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design

The Effects of the COVID-19 Pandemic on the Clinical Practices of Cardiologists

Management of acute coronary syndrome : ESC guidelines 2023

Impact of Society Guidelines on Trends in Use of Newer P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours

Efficacy and Safety of Ticagrelor versus Clopidogrel with Different Dosage in High-risk Patients with Acute Coronary Syndrome

Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes

Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes

Evaluation of pharmacist-led transition of care program in patients with acute coronary syndrome

Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry

Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention

Timing, Selection, Modulation, and Duration of P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI

Assessment of cardiac parameters after the administration of nicorandil before primary percutaneous coronary intervention

Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When

P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes

Aktive Filter

Suchergebnisse filtern